Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Company Profile
- CEO
- Chris Winter
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 1
- Beta
- 0.87
- Country
- LT
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -20.77
Financials
Revenue
$0.00-100.0%Net Income
$-552.0KEBITDA
$-414.5KFree Cash Flow
$-414.3KEPS (diluted)
$-0.00Shares Outstanding (diluted)
153.92M+485.6%Operating Expenses
$414.5KCash & Debt
$83.6KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-1.75M | $-0.01 |
| 2024 | $0.00 | $-1.14M | $-0.01 |
| 2023 | $0.00 | $-2.13M | $-0.02 |
| 2022 | $276.3K | $-348.9K | $-0.01 |
| 2021 | $921.3K | $-126.5K | $-0.00 |
| 2020 | $1.21M | $-302.3K | $-0.01 |
| 2019 | $717.5K | $-69.6K | $-0.00 |
| 2018 | $0.00 | $-78.2K | $-0.00 |
| 2017 | $0.00 | $-738.63 | $-0.00 |
Valuation
AVAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·6d ago·Neutral
…essfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its joint venture partner Austrianova, today announced the successful encapsulation of GMP-quality Klotho-producing cells in the joint venture's signature technology, …
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference Avaí Bio and Austrianova presented an encapsulated-cell approach to sustained α-Klotho delivery via Klothonova at the 2026 Klotho Conference in Miami.
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy Avaí Bio and Austrianova complete viral and adventitious agent testing of the Master Cell Bank and establish a Working Cell Bank for α-Klotho therapy.
View source ↗ - Newsaccessnewswire.com·47d ago·Neutral
Avant Brands Completes EU GMP Audit at Flowr Facility KELOWNA, BC / ACCESS Newswire / August 20, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the completion of its European Union Good Manufacturing Practice ("EU GMP") audit at the Company's largest cultivation facility, The Flowr Group Okanagan Inc. ("Flowr"), located in Kelowna, B.C. Completion of the on-site audit represents an important step in Avant's efforts to obtain EU GMP ce
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the deve
View source ↗
Congress trades
No disclosed congressional trades in AVAI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.